{"@id":"https://bioecon.ru/technology/exosome-therapies/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/exosome-therapies/","json":"https://en.bioecon.ru/api/v1/technology/exosome-therapies/index.json"},"id":"exosome-therapies","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/impacfat/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/umami-bioworks/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/pbs-biotech/","https://bioecon.ru/companies/spiber-technologies-ab/"]},"maturity":7,"name":"Exosome Therapies","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Perfusion bioreactor harvest"},{"n":2,"title":"Tangential flow ultrafiltration (TFF)"},{"n":3,"title":"Surface targeting ligand engineering"},{"n":4,"title":"In-vivo regenerative \u0026 anti-inflammatory efficacy"}],"summary":"Industrial scalable biomanufacturing, tangential flow filtration, and surface-ligand bio-engineering of nanoscale extracellular vesicles (30–150 nm) derived from stem cells or engineered immune cells, serving as potent cell-free regenerative medicines or targeted drug delivery carriers across the blood-brain barrier.","url":"/technology/exosome-therapies/","verified":"2026-11-22"}